Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,115.30 +36.44 (+0.45%) Bitcoin USD
64,205.29 +480.50 (+0.75%) CMC Crypto 200
1,385.40 -11.13 (-0.80%)
Clene Inc. (CLNN)
After hours:
| Previous close | 0.3370 |
| Open | 0.3384 |
| Bid | 0.3417 x 100 |
| Ask | 0.3487 x 100 |
| Day's range | 0.3325 - 0.3550 |
| 52-week range | 0.2500 - 1.0900 |
| Volume | |
| Avg. volume | 926,933 |
| Market cap | 44.502M |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
Simply Wall St.Bullish Clene Insiders Loaded Up On US$9.58m Of Stock
Quite a few insiders have dramatically grown their holdings in Clene Inc. ( NASDAQ:CLNN ) over the past 12 months. An...
GlobeNewswireEvidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Significantly improved clinical outcomes associated with long-term daily oral CNM-Au8® 30 mg treatment (change from original baseline; p<0.05)Long-term CNM-Au8 treatment, encompassing up to three years, was well-tolerated; no significant safety findings were observedFirst Phase 2 clini
GlobeNewswireIBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN), recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. The
